Rare among biotech hubs, MBI (Michigan Biotechnology Institute) is both a premier multidisciplinary center sought out by industry partners for unique derisking capabilities and a 501(c)(3) not-for-profit inspired by a mission to enhance quality of life by collaboratively accelerating the commercialization of sustainable biobased technologies. Consistent with that mission, we share select technologies—those that show the promise of game-changing sustainability—with the global community through low-cost, non-exclusive licensing.
MBI is known in the industrial biotechnology field for pioneering derisking, a process that quickly and cost-effectively fails flawed technologies while accelerating viable ones through a milestone-based, stage-gated innovation process. Seasoned team members—drawing on expertise from science, engineering and business—roadmap, prioritize, and address technical and commercial risks to effectively and efficiently accelerate early-stage technologies to market-readiness. This novel approach was conceived and championed by CEO Bobby Bringi, who brought to MBI crucial lessons from his entrepreneurial experience developing and successfully commercializing a biobased technology for anti-cancer drug production.
MBI applies the derisking approach to the development of biofuels, chemicals, food, and feed from renewable, rather than fossil, raw materials. We engage with universities, corporations and research institutions—and our long list of collaborators includes DuPont, Genomatica, Novozymes, NatureWorks, and the Great Lakes Bioenergy Research Center. Technologies developed at MBI are recognized and trusted worldwide. Take just one example: Together with Michigan State University (MSU) and Cargill, MBI was responsible for developing PLA, the polymer used, today, worldwide to make renewable and biodegradable containers and cutlery.
Founded in 1981, Lansing, Michigan-based MBI is closely affiliated with MSU and is a wholly owned subsidiary of the Michigan State University Foundation.